Author of

• 28122

  +

  Best abstracts selected from submissions 2 (ID 2)

  • Event: ACLC 2018
  • Type: Oral Session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 11/08/2018, 16:20 - 17:00, Jade Ballroom

  • 28222

    +

    OA04 - Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After (ID 154)

    16:20 - 17:00  |  Author(s): H. Horinouchi
    • Abstract

    Background:
    Patients with EGFR-mutation-positive non-small-cell lung cancer (EGFR-NSCLC) who are treated with both cytotoxic chemotherapy and EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have better survival outcomes than those who are only treated with EGFR-TKIs. Limited information is available about the factors that influence the non-administration of cytotoxic chemotherapies after the failure of EGFR-TKIs.
    
    
    Method:
    We reviewed the medical records of EGFR-NSCLC patients who received EGFR-TKIs as a first-line treatment at the National Cancer Center Hospital between January 2010 and December 2016. Computed tomography data regarding the number of metastatic organs, at the time of progressive disease (PD), which reflects the tumor burden, was retrieved. EGFR-TKIs use beyond PD was also investigated. We performed a multivariate logistic regression analysis to determine the factors influencing the non-administration of cytotoxic chemotherapies.
    
    
    Results:
    A total of 393 patients received EGFR-TKIs as a first-line treatment during the study period. After the exclusion of 96 patients who were receiving ongoing EGFR-TKIs treatment, 297 patients (103 men, 194 women) were included in this analysis. The median age was 68 years (range, 33?87 years), and 291 patients had an adenocarcinoma histology; 155 had deletions in exon 19, 132 had the L858R point mutation in exon 21, and 10 had other minor mutations. An Eastern Cooperative Oncology Group performance status (PS) of 0

• 28120

  +

  Poster Session (ID 8)

  • Event: ACLC 2018
  • Type: Poster Session
  • Track:
  • Presentations: 3
  • Moderators:
  • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall

  • 28188

    +

    P023 - Factors associated with administration of subsequent cytotoxic chemotherapy after nivolumab in patients with advanced NSCLC (ID 164)

    00:00 - 00:00  |  Author(s): H. Horinouchi
    • Abstract

    Background:
    Immune checkpoint inhibitors, including nivolumab, have shown a promising clinical efficacy in patients with advanced non-small cell lung cancer (NSCLC). Based on the characteristic pattern of response and progression, however, there is substantial clinical concern about the timing of switching treatment after progressive disease in patients receiving nivolumab treatment.
    
    
    Method:
    We conducted a consecutive retrospective analysis of patients with advanced NSCLC treated with nivolumab as a second-line treatment at the National Cancer Center Hospital from December 2015 to November 2017. Clinical information including age, sex, performance status (PS), histology, and progressive disease (PD) situation at the point of the last dose of nivolumab were evaluated. We defined the PD situation as follows: continuation of nivolumab after worsening of imaging findings (beyond PD); PD after ?2 cycles of nivolumab without beyond PD (Early PD), and PD after 3? cycles of nivolumab without beyond PD as (Late PD).
    
    
    Results:
    A total of 213 patients received nivolumab; 109 of these patients received nivolumab as a second-line treatment. Finally, 105 patients (78 men, 27 women) without EGFR or ALK driver oncogene mutations were included in this analysis. The patients' characteristics were as follows: male/female, 78/27 patients; median age (range), 63 (34-83) years; PS 0/1/2/3/4, 19/57/18/6/5 patients; and non-squamous/squamous histology, 77/28 patients. Four patients were treated beyond PD. The median number of nivolumab treatment cycles was 6, the objective response rate was 16%, and the median progression-free survival was 3.9 months (95% confidence interval: 2.5-6.0 months ). Among the 90 patients with disease progression, 42 patients (47%) received chemotherapy after nivolumab treatment. Among the patients with disease progression who did not receive chemotherapy after nivolumab treatment (48 patients, 53%), the main reasons for non-administration were a worsening of the patient

  • 28211

    +

    P050 - Long-Term Survival of Stage IIIA-N2 NSCLC Patients with Interstitial Lung Diseases (ID 210)

    00:00 - 00:00  |  Author(s): H. Horinouchi
    • Abstract

    Background:
    Interstitial lung diseases (ILD) frequently occur in patients with lung cancer. The optimal treatment strategy for non-small-cell lung cancer (NSCLC) patients with ILD remains unclear. We reviewed the efficacy and safety of surgery, chemotherapy, and radiotherapy.
    
    
    Method:
    We analyzed the medical records of patients with clinical stage IIIA-N2 NSCLC with ILD who were treated at our hospital between 2001 and 2016.
    
    
    Results:
    505 patients with clinical stage IIIA-N2 NSCLC were included. Of these patients with ILD, treatments included surgical resection (S) in 14 patients, chemoradiotherapy (CRT) in 7 patients, palliative chemotherapy (C) in 7 patients and palliative radiotherapy in one patient.The median follow-up period was 38 months. The patients' characteristics were as follows S/CRT/C: male, 26/6/7 patients; median age (range), 69 (58-82)/69 (60-75)/69 (35-82) years. Of the S, pathological stage IA/IIA/IIB/IIIA/IIIB, 1/1/2/9/1 patients. The median progression-free survival times were 9.5 months (95% CI: 5.3-45.3 months) in S, 45.9 months (95% CI: 7.2 months- not reached [NR]) in CRT, and 5.0 months (95% CI: 0.5-10.5 months) in C. The median overall survival time were 33.3 months (95% CI: 9.8 months-NR) in S, 45.9 months (95% CI: 8.3 months-NR) in CRT, and 9.9 months (95% CI: 1.6-42.4 months) in C. One patient died within 1 month of surgical resection. Acute exacerbations of ILD (AE-ILD) were noted in 14 % of the patients; 3 patients after surgery and 1 patient after chemoradiotherapy.
    
    
    Conclusion:
    The surgery and chemoradiotherapy can be considered as a treatment option for selected patients with IIIA-N2 NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits.

  • 28213

    +

    P080 - Efficacy and Safety of Docetaxel Plus Ramucirumab: A Consecutive Analysis of 68 Patients with Advanced NSCLC (ID 214)

    00:00 - 00:00  |  Author(s): H. Horinouchi
    • Abstract

    Background:
    Docetaxel plus ramucirumab (DTX+RAM) prolongs survival in patients with non-small cell lung cancer (NSCLC) with disease progression after platinum-based therapy. We assessed the efficacy and safety, especially the incidence of febrile neutropenia (FN), in patients who received DTX+RAM.
    
    
    Method:
    Consecutive patients who received DTX+RAM between August 2016 and May 2018 were reviewed retrospectively.
    
    
    Results:
    A total 68 patients received DTX+RAM. The patients